# Immunorock

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/immunorock

- Industry: Biotechnology
- Headquarters: Kobe-shi, Japan
- Website: https://immunorock.com
- Total disclosed funding: $2.3M
- Latest round: Seed (Jul 18, 2025)
- Investors on record: 3

## About

Founded in 2021 and based in Kobe, Japan, Immunorock Co, Ltd., d.b.a Immunorock, operates as a biopharmaceutical company that offers an oral vaccine platform that utilizes the properties of Bifidobacterium for mucosal immunization. As of 2023, the company is led by its CEO Toshiro Shirakawa. In December 2025, Immunorock Co, Ltd. raised JPY 50.1 million in seed B funding ?from KNC Laboratories Co., Ltd. and Kobe Shinkin bank.

The company develops a cancer immunotherapy drug that uses an oral vaccine platform technology. It is developing an oral cancer treatment vaccine (B440) and a coronavirus preventive vaccine (BCOV332).  

The company plans to use the December 2025 funding  to expedite clinical development, ensuring that B440, the first oral cancer immunotherapy agent globally, is made available to patients afflicted with cancer at the earliest opportunity.

## Funding rounds

- Seed, Jul 18, 2025, $1.3M — Osaka University Venture Capital, Kobe University Capital
- Seed, Apr 26, 2024, $0.3M — Osaka University Venture Capital
- Seed, Jul 14, 2023, $0.8M — Osaka University Venture Capital, MIRAIDOOR, Kobe University Capital

## Investors

- Osaka University Venture Capital (https://capitalatlas.ai/funds/osaka-university-venture-capital) — Seed
- MIRAIDOOR (https://capitalatlas.ai/funds/miraidoor) — Seed
- Kobe University Capital (https://capitalatlas.ai/funds/kobe-university-capital) — Seed